MedPath

Linaclotide

Generic Name
Linaclotide
Brand Names
Constella, Linzess
Drug Type
Small Molecule
Chemical Formula
C59H79N15O21S6
CAS Number
851199-59-2
Unique Ingredient Identifier
N0TXR0XR5X
Background

Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist. Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin derived from Escherichia coli, the first natural ligand that activates GC-C.

Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012. It gained EMA and Health Canada approval on November 26, 2012 and December 3, 2013, respectively. Linaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.

Indication

Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation in adults. This indication is approved in the US, Canada, and Europe.

In the US and Canada, it is also indicated for the treatment of chronic idiopathic constipation in adults.

In the US, it is also indicated for the treatment of functional constipation in pediatric patients 6 to 17 years of age.

Associated Conditions
Functional Constipation (FC), Irritable Bowel Syndrome With Constipation (IBS-C), Chronic idiopathic constipation (CIC)
Clinical Trials
Related News

Ironwood Pharmaceuticals Faces Setback as FDA Requires Additional Phase 3 Trial for Apraglutide

• Ironwood Pharmaceuticals' stock plummeted by 37% after the FDA required a confirmatory Phase 3 trial for apraglutide, a treatment for short bowel syndrome with intestinal failure. • Pharmacokinetic analysis revealed that exposure and dosing in the original STARS Phase 3 trial were lower than intended due to preparation and administration issues. • Despite promising efficacy data showing 27 patients achieving enteral autonomy in the long-term extension trial, the company has engaged Goldman Sachs to explore strategic alternatives.

Ironwood Pharmaceuticals Faces Setback in Apraglutide Development for Short Bowel Syndrome

• Ironwood Pharmaceuticals has announced that a confirmatory Phase 3 trial will be required for apraglutide in short bowel syndrome with intestinal failure, following its $1 billion acquisition of VectivBio. • The GLP-2 analogue apraglutide was positioned as a potential blockbuster drug with projected annual sales of $1 billion, offering advantages over existing treatments like Takeda's Gattex through improved potency and weekly dosing. • Ironwood has engaged Goldman Sachs to explore strategic alternatives for the company while continuing the long-term extension study and working with the FDA on the design of the confirmatory trial.

Sana Biotechnology Achieves Breakthrough in Type 1 Diabetes Treatment Without Immunosuppression

Sana Biotechnology has reported promising early trial results for type 1 diabetes treatment using allogeneic pancreatic islet cell transplantation without the need for immunosuppression. This groundbreaking development represents the first human evidence of successfully overcoming both allogeneic and autoimmune rejection in type 1 diabetes treatment.

Tenax Therapeutics Appoints Gillian Andor as VP of Clinical Operations to Bolster Phase 3 Program

• Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103). • Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study. • Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). • The appointment signifies Tenax's commitment to strengthening its clinical development capabilities as it prepares for potential global regulatory filings.

Medicare to Negotiate Single Price for Novo's Semaglutide Products Including Ozempic and Wegovy

• Medicare has selected semaglutide as one of 15 drugs for its second round of price negotiations, treating all formulations including Ozempic, Wegovy, and Rybelsus as a single product. • The negotiations will establish a unified "maximum fair price" for all semaglutide products, impacting Novo Nordisk's medications that currently list at $998-$1,349 per month. • CMS's approach focuses on the drug's active moiety rather than individual brand names, aiming to prevent "product hopping" and ensure consistent pricing across different formulations.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy